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Therapeutic nanoparticles (NPs) have great potential to deliver drugs against human diseases. 
Encapsulation of drugs in NPs protects them from being metabolized, while they are delivered 
specifically to a target site, thereby reducing toxicity and other side-effects. However, non-
specific tissue accumulation of NPs, for example in macrophages, especially in the spleen and 
liver is a general problem with many NPs being developed for cancer therapy. To address the 
problem of non-specific tissue accumulation of NPs we describe the development of the 
zebrafish embryo as a transparent vertebrate system for characterization of NPs against cancer. 
We show that injection of human cancer cells results in tumor-like structures, and that 
subsequently injected fluorescent NPs, either made of polystyrene or liposomes can be 
imaged in real-time. NP biodistribution and general in vivo properties can be easily monitored 
in embryos having selective fluorescent labeling of specific tissues. We demonstrate in vitro, 
by using optical tweezer micromanipulation, microscopy and flow cytometry that 
polyethylene glycol (PEG) coating of NPs decreases the level of adhesion of NPs to 
macrophages, and also to cancer cells. In vivo in zebrafish embryos, PEG coating resulted in 
longer NP circulation times, decreased macrophage uptake, and reduced adhesion to the 
endothelium. Importantly, liposomes were observed to accumulate passively and selectively 
in tumor-like structures comprised of human cancer cells. These results show that zebrafish 
embryo is a powerful system for microscopy-based screening of NPs on the route to 
preclinical testing. 
Introduction 
Cancer is a major global health problem and cancer therapy is painful and demanding for 
patients 
1
. Current anti-cancer drugs are often highly toxic and have severe side effects, such 
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as nausea, vomiting and loss of hair, and the prolonged systemic distribution causes a 
dramatic decrease in  the quality of life in cancer patients 
2
. Because high toxicity limits dose 
it is impossible to use the full therapeutic potential of anti-cancer drugs. Further, it is difficult 
to deliver anti-cancer drugs to tumors when they are distributed systemically in its free form; 
rapid excretion transports the drug out of the body, their often hydrophobic nature results in 
poor solubility and, finally, free drugs are prone to be metabolized before reaching the target 
3
. 
As a consequence drugs must be given frequently in multiple rounds to assure drug levels 
above minimum therapeutic concentration in tumor tissues. Thus, more efficient cancer 
therapy associated with fewer side-effects is desirable.  
The introduction of nanotechnology for cancer therapy has the potential to improve the 
efficiency of current anti-cancer drugs and quality of life in cancer patients during treatment. 
There are at least 23 NP-therapies that are either in clinical use or under clinical investigation 
4
. The aim is to deliver anti-cancer drugs encapsulated inside NPs specifically to tumors and 
thereby increase the drug concentration at target sites and to reduce off-target toxic effects. 
Nanotherapies used in the clinic today have the capacity to reduce side-effects but in general 
they only provide therapeutic efficacy that is comparable to conventional cancer therapy 
5, 6
. 
This suggests that nanomedicine is still in its infancy.  
The zebrafish (ZF) model has gained popularity over the past two decades as a model 
for human diseases, including cancer. This model supports growth of human cancer cell lines 
that show many similarities to the behavior of tumors in mammalian models such as mice 
7, 8
. 
Further, when zebrafish are exposed to carcinogens they develop tumors in virtually all 
organs with similar histology to human tumors 
9
. Sequencing of the ZF genome has revealed 
that 70 % of human genes have at least one ZF orthologue; thus, many of the same molecular 
and cellular components are involved in the initiation and development of diseases 
7, 10
. 
Moreover, since the ZF embryo lacks a functional adaptive immune system during its first 
month of development
11
, this system is increasingly being used to study exogenous human or 
mouse cancer cells to form tumors as there is no need for active suppression of the immune 
system to avoid rejection of injected human cells 
7, 12-14
. 
An especially valued aspect of the ZF system is that the embryo is optically 
transparent and tissues can be imaged in detail down to the single cell level, a unique feature 
for a vertebrate research animal 
7
. Consequently, the biggest advantage of this model for 
cancer research is that tumor growth can be studied by microscopic imaging at high resolution 
over time in a living organism 
15
. This system allows exogenously injected human tumor cell 
growth and tumor formation to be monitored in real time, with high spatial and temporal 
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resolution. The ZF optical transparency also enables in vivo studies of other fluorescent 
objects such as NPs. For example, binding of some NPs to endothelial cells has been 
described as an undesirable characteristic. However, with a few exceptions 
16-21
 there has been 
little analysis of interactions of NPs with endothelial cells in vivo.  
Most studies combining nanotechnology and ZF have focused on evaluation of 
toxicity, by assessing the potential toxic effect that NPs of different chemical composition 
have on normal development 
22-24
. Regarding nanotherapy, Wagner et al. showed that 
antibody labeled gold NPs are able to specifically kill cancer cells in the ZF embryo. When 
heated by a short laser pulse, the gold NPs generated a plasmonic nanobubble which 
selectively killed the cancer cells 
25
. However, in this case the cancer cells were pre-labelled 
with gold NPs before injection into the ZF embryo. Other studies have shown that NPs do 
have an effect on growth of cancer cells injected into zebrafish embryos. However, the NPs 
were introduced via bath-treatment and no evidence was presented to show presence of NPs 
in tumor-tissues 
26-28
. Our interest here is to use the ZF embryo to facilitate the development 
of NPs against human cancer that accumulates in tumors after their injection in the circulatory 
system. We have previously shown that NPs encapsulating an antibiotic are effectively taken 
up by macrophages in ZF embryos and kill Mycobacterium marinum, the model bacteria for 
tuberculosis (TB) 
29
. An important feature of this TB model-system is that the macrophages 
that take up the NPs are precisely the same cells where the mycobacteria reside. In stark 
contrast to TB, NPs for cancer therapy must be fabricated such that they avoid macrophage 
uptake and thereby stay as long as possible in the circulation to maximize the amount of NPs 
reaching the tumor. This so-called ‘stealth’ property of NP’s is a major focus of research in all 
applications of NPs against cancer. The ultimate goal is to develop a so- called “magic bullet” 
having features such as the ability to leak out of the vasculature at the tumor site and 
accumulate in tumor tissues, followed by selective uptake into the cancer cells where the drug 
is released, thereby killing them 
30-33
. 
We introduce the ZF embryo model as a fast screening tool for the development of NP 
therapies against cancer. Transgenic ZF lines that selectively express fluorescent proteins in 
selective tissues, for example the vasculature or macrophages, provide highly sophisticated 
tools for precise and detailed observation of the role of these tissues in development of tumors, 
as well as a precise tool to evaluate NP biodistribution. 
Here we show that coating of NPs with PEG reduces NP adhesion to macrophages in 
vitro. This effect of PEGylation was also assessed in vivo in the ZF embryo model and it was 
found that the PEG NPs showed increased circulation time, reduced macrophage uptake, and 
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reduced affinity for the endothelium associated with the circulatory system. Further, we 
demonstrate in vivo that NPs having good circulation properties accumulate specifically in 
regions where human cancer cells reside.  Together, this demonstrates the suitability of the 
zebrafish as an in vivo model to characterize the biodistribution of NPs, their circulation 
properties and the passive targeting of human tumor-like structures.  
 
Methods 
Nanoparticle preparation and characterization. For detailed explanation of liposome 
preparation, see Myhren et al 
34
. The liposomes were stored at 4
°
C in light-proof containers, 
and used for experiments for up to 2 weeks after synthesis. 
Three fluorescent monodispersed Fluoresbrite® Carboxylate Microspheres (PSNPs) (PS-
COOH, 2.6% solid (w/v) aqueous suspensions) were purchased from Polysciences, Inc.; Two 
bright blue (BB) carboxylate microspheres (particles size: 0.49µm and 0.997µm) containing 
dyes (coumarin) with excitation maxima 360 nm, and one yellow-green (YG) carboxylate 
microsphere (particles size: 0.19 µm) containing dyes (fluorescein) with excitation maxima 
441 nm. α-Amino-ω-methoxy-poly(ethylene glycol) 5000 (MPEG5k-NH2) was synthesized 
according to a previous report 
35
. The other chemicals, HOBt (1-hydroxybenzotrizole), EDAC 
(1-dimethylaminopropyl-ethylcarbodiimide hydrochloride), NHS (N-hydroxysuccinimide), 
barium hydroxide solution (0.05M) were purchased from Sigma-Aldrich and used without 
further purification, unless otherwise stated. 
For the “brush-like” immobilization of the MPEG5000-NH2 on the surface of carboxylate 
microspheres, we adapted a procedure from a previous report by using EDAC in the presence 
of HOBt in an aqueous solution at 4
°
C (Scheme 1) 
36, 37
. The larger PEGylated particles 
(0.49µm and 0.997µm) were purified by centrifugation at 10 000 g for 10 min at RT, washed 
once with 0.01 M HCl and three times with PBS-buffered solution (pH 7.4) via re-dispersion 
and centrifugation. Finally, the particles were re-suspended in PBS (0.044 wt% for 0.997µm 
and 0.344 wt% for 0.49µm PEGylation particles) and stored at 4
°
C until use. The smaller 
PEGylated NPs (0.19µm) were purified by dialysis, first against distilled water and then 
against PBS (pH 7.4) at 4
o
C for 3 weeks using a dialysis membrane of regenerated cellulose 
with a molecular weight cut-off of 8000. Finally, the suspension in PBS was stored at 4
°
C (the 
concentration: 0.443 wt% for 0.19µm PEGylated NPs) were determined by using UV-Vis 
photometer (the absorbance of the maximum peak vs particles concentration according to the 
Beer-Lambert law). 




Fish care and treatment. The ZF line AB (wt) was used for the following experiments: 
quantification of growth of human cancer cells, to study liposome accumulation in tumor-like 
structures, to analyze NPs circulation time and endothelium affinity. The ZF line 
Tg(fli1:EGFP)y1 was used to study the relation between ZF vasculature and injected human 
cancer cells, and to confirm that endothelium was the tissue to which PSNPs adhered. The ZF 
line Tg(mpeg1:mCherry)
UMSF001
 was used to study in vivo macrophage uptake of NPs. 
Embryos were kept in standard embryo water containing 0.003% phenylthiourea (Aldrich) in 
Petri dishes at 28.5°C. Embryos injected with human cancer cells were kept at 35°C and no 
adverse effects on their development were observed. The experiments were conducted in 
agreement with the provisions enforced by the Norwegian national animal research authority 
(NARA). 
 
Cancer cell lines. The human metastatic melanoma cell line Melmet 5 was established from a 
lymph node biopsy of a metastatic melanoma patient at the department of Tumor Biology, 
The Norwegian Radium Hospital, as described previously 
38
. Melmet 5 were maintained in 
culture in RPMI1640 medium (Lonza) completed with 10% FBS (Saveen & Werner) and 2 % 
penicillin-streptomycin (Lonza). Melmet 5 was transduced and stably expresses a dsRed 
fluorescent marker for visualization. The commercially available human cell line HEK293 
was maintained in culture in DMEM (Lonza) completed with 10% fetal bovine serum and 2 % 
penicillin-streptomycin (Lonza). HEK293 (ATCC) was transduced and stably expresses a 
mCherry fluorescent marker for visualization. Both cell lines were incubated at 37°C, 5% 
CO2. The growth medium was changed every third day and cells were passaged following 
standard protocols prior to reaching confluence. When passaged or prepared for ZF injections 
Versene (Life Technologies) rather than trypsin were used to preserve the molecular profile 
on the cell membrane. 
 
In vitro assay for macrophage nanoparticle uptake. The PSNP (Polysciences Inc.) 
solutions were prepared to get 100 multiplicity of infection (MOI) and 20 MOI. They were 
sonicated for 10 min before dilution. RAW macrophages were seeded in small individual 
dishes compatible with confocal imaging in RPMI1640 medium and left overnight for 
adhesion. Next morning, the PSNPs were mixed in RPMI1640 in a concentration of 2x10
8
/ml. 
Cell medium containing PSNPs was added to the cell dishes and incubated for 4 h. The cells 
were subsequently washed 3 times with PBS to remove free PSNPs. Next, fresh medium was 
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added before confocal imaging was performed. For liposome uptake experiments cells were 
seeded in the same way. The next morning a 1 % liposomes solution was prepared in PBS and 
the PBS/liposome solution was incubated with the RAW macrophages for 10 minutes. The 
cells were washed and imaged as described for PSNPs.  
Flow cytometry analysis: For flow cytometry analysis RAW cells were seeded at 
1x10
6
 cells per well in a 12 well dish in 1 mL medium and left for 4 h to allow adhesion. The 
NoPEG and PEG PSNP suspensions were added to the cells and mixed gently by swirling and 
incubated for 4 h. Liposomes were added to RAW cells in PBS and incubated for 10 min. 









 in the fridge for 10 min. Subsequently, cells were scraped off 





. Cells were kept on ice until the flow cytometry analysis. Analysis was 
performed using a FACSCalibur (BD Bioscience, New Jersey, USA) and Flowing Software 
2.5.1. (Turku Centre of Biotochnology, University of Turku, Finland). 
Cell debris and dead cells were excluded from analysis based on their forward and side scatter 




ZF injections. Embryos were injected using a glass needle (Harvard apparatus) controlled 
with a Narishige MN-153 micromanipulator connected to an Eppendorf FemtoJet express. 
Microscopic visualization of the fish during injections was facilitated by a stereomicroscope 
Leica DFC365FX with a 1.0X Planapo lens. 
Cancer cell injections: Cancer cells were grown in a T25 flask and harvested as described in 
the cell line section when reaching about 85% confluence. The cell suspension was 
centrifuged in a 15 ml Falcon tube, washed once with PBS without re-suspending the pellet. 
PBS was removed until the pellet was only partially covered and re-suspended in the small 
remaining PBS. In order to establish the number of cells to be engrafted test injections were 
done in a drop of water on the lid of a petri dish. The injection pressure or injection time was 
adjusted to obtain the desired number of cells per injection. Two dpf embryos were 
anesthetized with tricaine as described in Gao et al. 
39
 and 200-300 cancer cells were injected 
in the lower part of Duct of Cuvier
7
 (see Figure 1a). 24 h post injection embryos were 
screened for tumor-like structures in the tail. 
Page 6 of 34Nanoscale
7 
 
Nanoparticle injections: To study nanoparticle behavior in ZF embryos 2 dpf embryos were 
anesthetized as described above. A glass needle was prepared so that the tip was narrower 
than the posterior cardinal vein. The injection site for NPs is marked in Figure 1A. 
Approximately 3 nl of nanoparticle suspension was injected. 
Accumulation of NPs in tumor-like structures: To study the potential for accumulation of NPs 
in the tumor-like structures in the tail of ZF embryos, two dpf embryos were injected with 
cancer cells as described above. Tumor-like structures were allowed to grow for two days and 
at four dpf, embryos with tumor-like structures in the tail and normal blood flow were 
injected with NPs. Embryos were anesthetized and inspected for potential accumulation of 
NPs in the tumor-like structures, using the Leica stereomicroscope, 2-5 h post injection of 
NPs.    
 
ZF imaging. A Leica DFC365FX stereomicroscope with a 1.0X Planapo lens was used for 
quantification of growth of the fluorescent tumor-like structures in ZF embryos. It was also 
used for imaging of fluorescent NPs in ZF embryos and acquisition of time lapse videos of 
circulating NPs in ZF embryos. Prior to imaging ZF embryos were anesthetized by adding 
tricaine to embryo water. Upon imaging embryos were placed on a petri dish on a 
polymerized 1.5% agarose bed with just enough embryo water to avoid drying the embryo. 
All time lapse videos in supplementary data are shown at 7 frames per second.  
An Olympus FluoView 1000 upright BX61WI confocal microscope was used for 
high-resolution microscopic imaging. Prior to imaging embryos were anesthetized in tricaine 
(Finquel, Argent Laboratories) as described in Gao et al.
39
 Subsequently, they were placed in 
a small dish with a glass bottom filled with low melting point agarose. Once the agarose 
polymerized, embryo water containing tricaine was added. We used a 40x water objective in 
Figure 1 and a 60x water objective in Figure 5 and 6. In Supplementary Figure 1 the blue dye 
Dextran (MW 10 000) was used. 3D view PlugIn in Fiji computer software was used in 
Figure 6 E and F. The laser lines for confocal fluorescence imaging used were 405 (blue), 488 
(green), 543 (red). 
 
Fluorescent Pixel Count (FPC).  The FPC was used to evaluate growth of injected cancer 
cells in the ZF embryos. The ZF was injected with cancer cells 2 dpf. The images were 
acquired at 2, 4 and 6 dpi using fluorescent stereomicroscopy with a Leica DFC365FX with a 
1.0x Planapo lens. The tail region of the fish was imaged and analyzed with FPC using 
ImageJ software. The same zoom, gain and exposure times were used for all time points, 
Page 7 of 34 Nanoscale
8 
 
although different settings were used for the two cancer cells lines. The fish were kept in 
individual wells in a 12-well plate during the experiments in order to track individual fish. 
The images were changed to 16-bit formats and pixel above lowest gray value of true signal 
was used to quantify the surface area of the tumor-like structure over the 3 time points. 
 
Optical Tweezers Experiments. Cancer cells or macrophages were seeded out in individual 
35mm glass bottom dishes coated with poly-D-lysine (MatTek). The cell suspension was 
diluted to contain approximately 25 000 cells/mL. 2 mL of this suspension was added to each 
dish. The cells had to be incubated at 37
°
C for at least 4 hours for them to adhere to the glass 
bottom dish before the experiment started. Before the experiment, the medium was removed, 
and the cells washed three times with PBS (Sigma). 2 mL of the solution containing the NPs 
were then added to the cells. Three different solutions with NPs were used for this experiment, 
PBS, RPMI-1640 (Sigma) or PBS with NPs incubated in mouse serum (Innovative Research 
Inc) for the macrophages or human serum (Innovative Research Inc) for the Melmet 5 cells.  
For NPs that were incubated with either mouse serum,  human serum or FBS (Saveen 
& Werner) 0.000065 wt % of the NPs where incubated with 0.5 mL of the respective solution 
for 15 min at room temperature (20-22
°
C) in a 1.5mL Eppendorf centrifuge tube. Then the 
NP-serum solution was centrifuged for 15 min at 15.000x g. The supernatant was removed 
carefully, to avoid re-suspending the pellet. 0.5mL of PBS was added, and the pellet re-
suspended. The solution was centrifuged for 15min at 15.000x g for 15min. This washing step 
was repeated one more time. After the last washing the supernatant was removed, 0.5 mL of 
PBS added and the pellet was re-suspended. 0.5 mL of the NP-solution was then diluted in 10 
mL of PBS in a 50 mL tube, and sonicated for 5 min to make the solution monodisperse. 
Before adding the NPs that were incubated with the serum to the cells, the cells were washed 
three times with 3 mL of PBS to remove residual growth medium. After washing, 2 mL of the 
NP solution was added to the cells. For the samples where the NPs are not incubated with 
serum, we followed the same protocol, but only used PBS. After incubation of NPs in serum 
all analysis of NP adhesion to cells was carried out in PBS to study the effect of the bound 
serum proteins only. 
 
SEM and TEM imaging. The liposomes were imaged using transmission electron 
microscopy (TEM) using a Philips CM100. A normal negative stain was applied using 2 % 
uranyl acetate. The polystyrene NPs were imaged with scanning electron microscopy (SEM) 
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using a Hitachi S-4800. The suspension of NPs was applied to the double-sided carbon tape 
and air-dried under a lamp for 30min. They were then coated with a 4nm layer of platinum. 
 
Statistics used. The statistics was done using Origin 9.1 software. For the in vitro optical 
tweezers and growth of the cancer cells after injection the Barnard’s Exact test was used to 
determine p-value, as the data were regarded as binary with regards to adhesion/no adhesion 
or growth/no-growth, respectively. Significance level is shown as **p<0.01, *p<0.05.  
The SE for the binary data was calculated using  
 = ()
 , where π=sample proportion of responders.    
 
Results and discussion 
Establishment of tumor-like structures in zebrafish embryos from injected human 
cancer cells. The zebrafish embryo is an established and accepted model for human cancer 40. 
Our starting point was to use cancer cells known to grow tumors in mice and inject them into 
zebrafish embryos. These tumors would then allow in vivo testing of nanoparticles in a 
vertebrate model for human cancer.  
Fluorescently labeled human cancer cells (200-300 cells, see Materials and Methods) 
were injected into the lower part of the Duct of Cuvier of ZF embryos 2 days post-fertilization 
(dpf) after which the dissemination of cancer cells via the vasculature to the tail tissue could 
be monitored by microscopy (Figure 1A). Embryos injected with human cancer cells were 
kept at 35°C as a compromise between the optimal temperatures for ZF embryos (28°C) and 
human cells (37°C). The human melanoma cell line Melmet 5 was first chosen because of the 
known capacity of these cells to establish solid tumors in mice 
38, 41
. Injected Melmet 5 cells 
extravasated from the embryo blood vessels within the first 24 h post injection. In the ZF 
embryos this cell line established both single and multiple tumor-like structures in the tail 
(Figure 1B). Using the transgenic ZF line Tg(fli1a:EGFP)
y1
, which has a GFP reporter gene 
expressed specifically in the endothelial cells 
42
, resulting in a green fluorescent vasculature, 
we could observe the cancer cell location relative to the blood vessels. At the site of 
extravasation and growth of the tumor-like structure the Melmet 5 cells generated “pockets” 
in between blood vessels as they pushed the vasculature aside (Figure 1 C-D). The blood flow 
was not observed to be affected by the presence of the tumor-like structure and no endothelial 
cells were seen to migrate into the tumor mass.  
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The human embryonic kidney cells (HEK293) were also tested due to their 
tumorigenicity and ability to establish solid tumors in mice 
43, 44
. For these cells, extravasation 
from the embryo blood vessels was also observed within the first 24 h. A striking 
characteristic of the HEK 293 cells was the generation of a single, prominent tumor-like 
structure in the tail of the embryo (Figure 1E). The relative location of the HEK293 tumor-
like structure to the vasculature was different from the Melmet 5 phenotype, as it was 
peripheral to the vasculature rather than in between the blood vessels (Figure 1F-G). Also 
here, the blood flow was unaffected and no endothelial cells migrated into the tumor-like 
structure. 
Quantifying the growth of the tumor-like structures every second day over a period of 
six days post-injection (Figure 1H) showed that extravasated Melmet 5 cells had an average 
growth in volume of 84 % from 2 days post injection (dpi) to 6 dpi, with variations among the 
individuals ranging from 13 % decrease in size to a 162 % increase in size. The HEK293 cells 
had a lower average growth (34 %), but a much higher degree of variation between embryos 
from 2 dpi to 6 dpi ranging from a 97 % decrease in size to a 250 % increase in size. Thus, 
Melmet 5 cells displayed a more consistent potential for sustained growth in the ZF embryo 
than the HEK293 cells.  
The results collectively demonstrate the ability of ZF embryos to support cell survival 
of our injected human cancer cell lines, and even expansion of the tumor-like structures. 
These experiments set the stage for using the ZF embryo as a system for monitoring NPs in a 
dynamic in vivo vertebrate model for human cancer.  
 
NPs without PEG have short circulation times in vivo. NPs without polyethylene glycol 
(PEG) coating are known to have short circulation times in vivo as they are more prone to 
clearance from circulation by macrophages 
45
. The transparency of the ZF embryo model 
offers the possibility of  fast, yet detailed in vivo investigation and imaging of the distribution 
of NPs throughout the organism 
29
. By visual inspection using stereomicroscopy, we 
evaluated the circulation times and biodistribution of both polystyrene nanoparticles (PSNP) 
and liposomes without PEG (NoPEG) in 2 dpf embryos. We chose to work with these PSNPs 
as they have a uniform size and their carboxylated surface makes surface modification easy. 




In order to study biodistribution and circulation abilities of PSNPs we injected a blue 
fluorescent version of NoPEG PSNPs (1000 nm) into the circulation of 2 dpf embryos of the 
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transgenic fish line Tg(fli1a:EGFP)
 y1
. This particular transgenic ZF line has green fluorescent 
vasculature and its role in the presence of PSNPs can be established. Using stereomicroscopy, 
it was evident that NoPEG PSNPs stopped circulating minutes after injection. They seemed to 
have a high affinity for the endothelium (Figure 2A), thereby hindering further circulation in 
the bloodstream.   
With the aim to quantify circulation times, green fluorescent 200 nm NoPEG PSNPs 
(Table 1), having the same surface characteristics as the 1000 nm NPs, were injected into wild 
type ZF embryos having no fluorescence in the vasculature. Twenty seconds post injection the 
PSNPs circulated (Figure 2B, asterisk) but a fraction had already adhered prominently to the 
endothelium, as evident by intense green immobile dots (Figure 2B, red arrows, 
Supplementary video 1). By 140 seconds post injection there were relatively low levels of 
NoPEG PSNPs left in the circulation (Figure 2C, white asterisk, Supplementary Video 2), 
while there was increasing adhesion to the endothelium. The NoPEG PSNPs did not 
discriminate between the different blood vessels and adhered in comparable amounts to the 
caudal artery (Figure 2C, yellow asterisk), caudal vein (Figure 2C, red asterisk) and the dorsal 
longitudinal anastomotic vessel (DLAV) (Figure 2C, white arrow). The intersegmental 
vessels (ISV) are visible due to circulating NoPEG PSNPs, showing that they did not adhere 
to these narrow blood vessels (Figure 2C, yellow arrow). 
Twenty minutes post injection there were no circulating NoPEG PSNPs due to their 
high affinity for the endothelium throughout the embryo. For example, individual endothelial 
cells could be observed in the caudal vein as a speckled pattern along the vasculature to which 
the NoPEG PSNPs had adhered (Figure 2D, green). The high affinity of the PSNPs for the 
endothelium appeared to be associated with toxicity as all the embryos died within 24 h. 
Analysis of the circulation time of green fluorescent NoPEG liposomes (average 
diameter 200 nm, Table 1) were also performed. Liposomes were injected into the circulation 
of wild type embryos and shortly after injection the liposomes circulated through all blood 
vessels and consequently a full representation of the vasculature was visible as a green 
fluorescent signal (Figure 2E), giving it a similar appearance to the Tg(fli1a:EGFP)
 y1
 fish. 
The circulation time of the NoPEG liposomes was several hours, significantly longer than 
NoPEG PSNPs. Infrequent events of random adhesion to the endothelium could be observed 
(Figure 2E, arrow) but liposome batches used within two weeks from their production did not 





 with red fluorescent macrophages enabled us to study their 
role in clearance of liposomes from circulation. Inspection of embryos 20 h post-injection 
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showed already a total clearance of liposomes from the circulation. From the injected mpeg 
cherry embryos it could be concluded that macrophages had cleared the liposomes from the 
circulation, as multiple yellow dots were visible in the tail, corresponding to the red 
macrophages filled with green liposomes (Figure 2F, arrows). Importantly, the liposomes did 
not adhere to the endothelium and showed no toxicity to the ZF embryos, in stark contrast to 
the NoPEG PSNPs.  
 
PEG coated NPs display stealth properties in vitro. The paradigm in the NP field is that 
PEG adds stealth properties to NPs. The prevailing theory to explain this phenomenon is that 
this process prevents opsonization by plasma proteins, and thereby macrophage uptake, 
resulting in prolonged circulation time 
5, 48-50
. To investigate how PEG-coating of NPs affects 
their interaction with different cell types, we performed incubation studies with cells in vitro. 
For this we chose the mouse macrophage RAW cell line which display classic macrophage 
behavior regarding uptake of foreign particles 
51, 52
. We used 200 nm commercial PSNPs and 
liposomes, shown by electron microscopy in Fig 3A. Green fluorescent 200 nm NoPEG or 
PEG PSNP were first added to the cell medium of RAW cell cultures and incubated for 4 
hours. After washing away unbound NPs, the cells were imaged by confocal microscopy. The 
images show that NoPEG PSNPs were taken up in high amounts, as the cells had acquired 
bright fluorescence from the NPs (Figure 3B-1). In contrast, the PEGylated PSNPs were taken 
up by the cells at much lower levels (Figure 3B-2). To quantify the levels taken up by 
macrophages we performed flow cytometry showing a two-fold increase in uptake of NoPEG 
PSNPs compared to PEG PSNPs (Figure 3C).  
The PEG effect was also studied using 200 nm liposomes (Table 1, Figure 3D).  Due 
to heavy aggregation of liposomes in the presence of serum in the cell medium this 
experiment had to be carried out in PBS. Liposomes in PBS were added to the RAW cells and 
incubated for only 10 minutes as titration experiments showed rapid influx of liposomes in 
RAW cells. Confocal analysis indicated that NoPEG (Figure 3D-1) and PEG liposomes 
(Figure 3D-2) were taken up in similar amounts by the cells. The rapid uptake of liposomes 
into macrophages resulted in a very short time window to study the effect of PEG and 
excluded them from reliable flow cytometry analysis. Collectively, these results show that 
PEGylation of PSNPs lowers their uptake by macrophages, a favorable result in the context of 
one of the biggest challenges for obtaining long circulating NPs.  
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Quantification of the effect of PEGylation of NPs using optical tweezers. The above data 
showed that PEG reduces the uptake of PSNPs by macrophages. In order to analyze the 
interactions between cells and PSNPs in more detail we carried out controlled 
micromanipulation using optical tweezers (OT). The OT makes it possible to quantify the 
interactions of individual PSNPs with a single cell under different conditions, in real time. 
The small size of the liposomes excluded them for this type of study. 
In these experiments there are three possible outcomes: 1) the OT is not strong enough 
to remove the NP from the cell, 2) the NP and cell can be moved apart but remain connected 
through a tether 
53
 or 3) the particle and cell can be moved apart, since no sufficiently strong 
adhesion has been made. Here, we classified the tethered particle as ‘adhered’. The adhesion 
percentage was then defined as the number of adhered particles/ total number of experimental 
attempts at adhesion x 100%. 
First, we tested whether the size of the NoPEG PSNPs was proportional to the degree 
of adhesion. Two sizes of PSNPs with a diameter of 1000 nm and 500 nm (Table 1) were used. 
We found that the 1000 nm NoPEG PSNP displayed a significantly higher binding affinity 
than the 500 nm NoPEG PSNPs (Figure 4A). NoPEG 500 nm PSNPs interacted strongly with 
RAW macrophages (85%) but compared to the 1000 nm particles they had a 10 % reduction 
in the level of adhesion. 
We next investigated whether PEGylation of the PSNPs would result in a lower 
adhesion to macrophages, as was expected based on our microscopy and flow cytometry 
experiments. Figure 4B shows snapshots of movies recorded of 1000 nm PSNPs, with or 
without PEG, pushed against a RAW macrophage. The striking difference is that the NoPEG 
PSNPs already adhered to the macrophage surface within seconds after the first contact and 
the macrophage started to engulf it within the first minute (Figure 4B, left panel, arrow, 
Supplementary Video 3). In contrast, a PEG PSNP did not stimulate such a response even 
after making multiple, transient, forced contacts with the RAW macrophage (Figure 4B, right 
panel, arrow, Supplementary Video 4). 
When quantifying the degree of adhesion and comparing NoPEG vs PEG PSNPs we 
indeed found that PEG added a measurable stealth effect to PSNPs in vitro. Coating the 1000 
nm PSNP with PEG significantly decreased their adhesion to macrophages (Figure 4C). A 
similar decrease in adhesion to macrophages was observed when coating 500 nm PSNPs with 
PEG. By comparing the degree of adhesion for the 1000 nm and 500 nm PSNPs with PEG 
coating, the relevance of size for adhesion was eliminated as both the 1000 nm and 500 nm 
showed similar affinity for the macrophages (Figure 4C). Importantly, compared to the 
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NoPEG PSNPs the degree of adhesion of the PEG PSNPs was reduced by 60-70 % (Figure 
4A). 
It is widely believed that the main effect of NP PEGylation in vivo is to reduce the 
binding of serum proteins and the process of opsonization. In the absence of PEG, serum 
proteins such as IgG and complement bind to the NPs and allow binding to receptors on the 
surface of phagocytic cells, such as macrophages 
54-56
. To address the potential role of 
opsonization by serum proteins we pre-incubated one set of 1000 nm PSNPs with undiluted 
mouse serum (for mouse macrophages). As controls, two other sets of PSNPs were incubated 
in either undiluted fetal bovine serum or phosphate-buffered saline (PBS) solution. The 
further examination of the interactions between NPs and cells was carried out in PBS. All 
three sets of NoPEG PSNPs were found to have high levels of adhesion to macrophages 
(above 75%). Conversely, the level of adhesion for PEG PSNPs was below 5% for all three 
sets (Figure 4D). This shows that while PEG lowers the interaction between PSNPs and RAW 
macrophages, serum had no additional effect on the interactions between NoPEG PSNPs and 
macrophages.   
In a subsequent set of experiments, we determined the adhesion of 1000 nm PSNPs to 
the human Melmet 5 cancer cells. Therefore, one set of PSNPs was pre-incubated in undiluted 
human serum (HS). NoPEG PSNPs adhered much weaker to the Melmet 5 cells compared to 
RAW macrophages and PEGylation further lowered the interaction between PSNPs and 
Melmet 5 cells. NoPEG PSNP had a degree of interaction above 65 % while the PEG PSNPs 
interaction with Melmet 5 cells were practically eliminated (Figure 4E). Note that NoPEG 
PSNPs pre-incubated in PBS adhered more frequently to Melmet 5 cells than NoPEG PSNPs 
pre-incubated with FBS and HS. 
The use of optical tweezers to quantify the effects of surface coating and other 
parameters of NPs is a novel and promising strategy. Optical tweezers allow the interactions 
between NPs and cells to be analyzed in a controlled and detailed manner. By trapping single 
NPs and bringing them in contact with cells, interaction times and adhesion forces were 
quantified. We found that the level of adhesion of NP to macrophages depends on the particle 
size and that PEG coating eliminates this effect. In addition, using this high precision 
technique we investigated how the presence of serum proteins on the surface of PSNPs 
influenced their interactions with RAW macrophages and whether PEG had an effect in this 
system. The classical idea is that PEG prevents opsonization; marking of foreign objects in 
the blood stream for recognition and uptake by macrophages 
57
. Implied in this idea is the fact 
that in the absence of PEG these serum opsonins are the main factors responsible for 
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macrophage uptake. However, in our experiments we failed to see any increased adhesion of 
NoPEG PSNPs to macrophages that were incubated with serum. Nevertheless, our results 
with optical tweezers show that the NoPEG PSNPs show high affinity binding to the 
macrophages in the absence of serum. This agrees with the data of Diakonova et. al who 
demonstrated that efficient internalization of latex beads by macrophages occurs in serum-free 
conditions 
58
. Even though it is difficult to define the responsible molecular players scavenger 
receptors have been suggested to be responsible for the non-specific, high-affinity binding of 
particles to macrophages 
59
.  
PEGylation of PSNPs significantly reduced binding to macrophages. However, for NPs in 
cancer therapy an additional challenge is to stimulate selective uptake by cancer cells while 
avoiding macrophage uptake 
60
. Therefore, we also investigated the interactions of PSNPs, 
with and without PEG, in the presence and absence of serum, with the human Melmet 5 
cancer cells. The PSNPs without PEG or serum interacted less efficiently with Melmet 5 cells 
than to macrophages. The addition of PEG completely blocked all measurable binding of 
PSNPs to these cancer cells, as previously shown for PEG NPs 
60
. However, with HEK293 
cells PEG PSNPs bound more than NoPEG PSNPs (data not shown). The effect of serum was 
also unpredictable. The data imply that serum reduces the ability of the NoPEG PSNPs to 
bind passively to Melmet 5 cells. The addition of serum had no effect on the inability of the 
PEG PSNPs to bind to the Melmet 5 cells. Therefore, our results with macrophages reveal a 
predictable stealth effect of PEG on PSNP binding and no significant effect of serum in this 
system. In contrast, it is more difficult to make general conclusions about serum or PEG in the 
binding of PSNPs to cancer cells.  
Although more detailed studies are needed to make more definitive conclusions, the 
simplest interpretation of our data in RAW macrophages is that in the absence of PEG on the 
surface of the PSNP, the particle bind directly to macrophage surface receptors. The PEG 
molecule directly, rather than indirectly via serum proteins, lowers the interactions between 
the PSNPs and macrophage surface receptors. By using the optical tweezer to study NP-cell 
interactions we demonstrate the potential of this method to generate detailed knowledge about 
how cells interact with NPs with different characteristics.  
 
 
PEGylation of NPs prolongs in vivo circulation time. Having demonstrated a clear stealth 
effect provided by PEG in vitro we next investigated whether this effect could also be 
observed in the zebrafish, resulting in prolonged NP circulation time in vivo. As described 
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above, NoPEG PSNPs displayed undesirable properties in the ZF embryo, such as short 
circulation times and a high general affinity for the endothelium as they did not discriminate 
between the different blood vessels in the tail (Figure 2C). We therefore investigated whether 
PEG could improve the quality of the PSNPs regarding these undesirable properties.  
Green fluorescent 200 nm PEG PSNPs (Table 1) were injected in the posterior 
cardinal vein of 2 dpf wt embryos (Figure 1A). 20 seconds post injection these particles were 
circulating (Figure 5A, white asterisk, supplementary video 5) and displayed relative low 
affinity for the endothelium. Further, they only adhered to the small vessels (Figure 5A, red 
arrow) in between the caudal artery (Figure 5A, yellow asterisk) and caudal vein (Figure 5A, 
red asterisk). 140 seconds post injection a relatively high amount of PEG PSNPs were still in 
circulation (Figure 5B, white asterisk). The PEG PSNPs discriminated between the different 
blood vessels, as vessels with strong blood flow did not attract PEG PSNPs; they did not 
adhere to the narrow DLAV vessels (Figure 5B, white arrow), the caudal artery (Figure 5B, 
yellow asterisk) nor the caudal vein (Figure 5B, red asterisk). Thus, the affinity of the PEG 
PSNPs was for the most part directed towards the smaller blood vessels (Figure 5B, red arrow) 
with natural, weaker blood flow (Supplementary video 6). The maximum detectable 
circulation time for PEG PSNPs was about 60 minutes, as evident when the NPs were injected 
into the Tg(mpeg1:mCherry)
UMSF001
 zebrafish line. At no time points did the green PEG 
PSNPs co-localize with the red fluorescent macrophages (Figure 5C), suggesting that they are 
adhered to the endothelium as the circulation time appeared to be too short for the 
macrophages to be able to take them up. 
We next carried out the same experiment with liposomes. The NoPEG version of the 
liposomes displayed circulation abilities, at first glance compatible with good stealth 
properties, as they did not attach to the endothelium. However, they were cleared from the 
circulation long before 20 h post injection by macrophages. Therefore we investigated 
whether the presence of PEG could delay this process. The addition of PEG to liposomes 
showed a distinct improvement since they stayed in circulation 24 hours post injection, as 
observed by the completely visible vasculature in the tail (Figure 5D, Supplementary Video 7). 
Even though the majority of the PEG liposomes were still circulating it was noteworthy that 
macrophages had begun to clear PEG liposomes from the circulation, as shown by using the 
ZF line with red fluorescent macrophages (Figure 5D, yellow, arrow). By 46 h post injection 
even more PEG liposomes were taken up by the macrophages (Figure 5E, green dots, arrows, 
Supplementary Video 8), but a considerable number of liposomes were still circulating. 
Inspection of the embryo by stereomicroscopy 70 h post injection showed a total clearance of 
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PEG liposomes from the blood circulation (Supplementary Video 9), since at this point they 
were all taken up by macrophages (Figure 5F, arrow). No liposomes were observed to adhere 
to the endothelium and importantly, the liposomes were evidently not toxic, as the embryos 
survived with liposomes present in the circulation for at least 50 h. The PEG molecules need 
to have a specific morphology and be oriented outwards from the NP surface to be effective. 
This morphology is known to change over time and become non-functional, which could 
explain the eventual uptake of PEG liposomes by macrophages 
61
. 
Using fluorescent polystyrene nanoparticles and liposomes, we demonstrate that the 
ZF embryo model makes it possible to follow the NPs from the time of injection up to the 
point when they are removed from circulation. We could identify two undesirable localization 
sites in the fish where NPs accumulated: the endothelium and the macrophages. The ability of 
endothelial cells to bind and to take up NPs has not been studied much in the field of NP 
therapy against cancer, even though it has been shown in one publication that the vasculature 
is indeed able to clear foreign objects from circulation in the zebrafish 
62
. The association of 
NPs with endothelial cells in vivo has been observed in mice 
21
, however methods available to 
routinely visualize NPs in mice may have have precluded identification of their potential 
binding to blood vessels 
17-19, 33, 63-66
. Earlier studies have described binding and uptake of 
latex particles to sinusoidal endothelial cells after perfusion of rat liver 
20
. Thus, adhesion of 
NPs to the endothelium seems therefore to be a poorly appreciated phenomenon. Drug-
containing NPs that adhere in a non-specific manner to the vasculature will likely have a high 
probability for toxic side-effects and this interaction must presumably be kept to a minimum. 
Tumor vasculature is considered a valid target in cancer therapy 
67
 and it is possible to target a 
sub-compartment of the vasculature with NPs 
68
. In vitro a considerable uptake of NPs by 
endothelial cells has been demonstrated and PEGylation of NPs lowers endothelial cell uptake 
69
. This is in agreement with our results, which show that PEGylated NPs circulates longer 
than NPs without PEG and PEGylation was associated with a marked reduction in the 
endothelial binding of NPs. This shows that the ZF embryo is a highly suitable in vivo model 
to quickly screen a panel of NPs in the search for candidates with desirable characteristics. 
In contrast to endothelium-NP interactions, the undesirable phenomenon of 
macrophage uptake of NPs from the circulation is well-characterized 
70, 71
. In mice, NP 
injections are routinely followed by killing the animal, removal of body fluid at the site of 
injection to harvest macrophages, centrifugation and filtering the re-suspended cell suspension 
before flow cytometry analysis 
72
. In contrast, in the ZF embryo model it is straightforward to 
monitor macrophage uptake of NPs directly by imaging techniques of live embryos, 
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especially when combined with the transgenic fish lines with fluorescently labeled 
macrophages. 
 
PEGylated liposomes accumulate passively and specifically to the region of human 
tumor-like structures in ZF embryos. The observed long circulation time of PEG liposomes 
makes them a promising candidate for testing their ability for passive targeting to the human 
tumor-like structures. Given that the NoPEG PSNPs were cleared relatively fast from the 
circulation we did not investigate their possible accumulation in the tumors.  
Melmet 5 or HEK293 cells were injected into 2 dpf wild type embryos and tumor-like 
structures were allowed to develop for two days. Embryos that fulfilled the two selection 
criteria of having tumor masses in the tail and a normal blood flow throughout the whole 
embryo were subsequently injected with PEG liposomes at 4 dpf into the posterior cardinal 
vein (Supplementary Video 10). Strikingly, imaging of these embryos revealed a specific and 
rapid accumulation of liposomes into tumor-like structures of both cell lines. For the Melmet 
5 cells liposomes accumulated specifically close to the sites of the tumor-like structure 
already at 2 h post injection. At this time-point, there were no liposomes taken up by 
macrophages or attached to the endothelium (Figure 6A). Some embryos having multiple 
tumor structures clearly showed the apparent specificity of the accumulation of liposomes to 
areas with cancer cells (Figure 6B, arrows, Supplementary Video 11). In Figure 6B, the tumor 
structures furthest to the right showed a pattern of liposomes adhering to the endothelium 
specifically in the area around cancer cells, opening up the possibility that Melmet 5 cells 
secrete factors that locally affect the vasculature.  
Tumor-like structures comprised of HEK293 were also able to strongly and selectively 
accumulate PEG liposomes within the tumor mass after 5 h (Figure 6C). However, liposomes 
seemed to accumulate more around the HEK293 tumor structures. This was in contrast to   
Melmet 5 structures, where liposomes seemed to have a tighter association with the tumor-
like structure. 
A control embryo not injected with cancer cells shows the distribution of the PEG 
liposomes after 6 h of circulation (Figure 6D). Some green “hotspots” can be observed 
(Figure 6D, arrows), that represent macrophages starting to clear liposomes from the 
circulation. Notably, there is no accumulation of liposomes elsewhere, in the absence of 
cancer cells.  
To verify the difference in the profile of liposome accumulation in Melmet 5 and 
HEK293 tumor-like structures observed in Figure 6A and 6C, respectively, we performed 
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confocal microscopy to study the pattern in more detail. Two embryos with tumor-like 
structures were examined by acquisition of confocal stacks. A 3D-view of the Melmet 5 
tumors showed a tight association between liposomes and the Melmet 5 cells (Figure 6E, 
Supplementary Video 12). Some liposomes seem to have penetrated into the tumor mass 
(Figure 6E, arrow) but the majority were located at the periphery. It is not clear if the 
liposomes were taken up by the Melmet 5 cells or whether they were located on the surface of 
the cancer cells. The HEK293 tumor-like structure, in contrast, showed a looser association 
with the liposomes (Figure 6F, Supplementary Video 13). Liposomes were located at the 
areas around the tumor-like structure but were not taken up by the cancer cells. This image 
could suggest that most liposomes are not yet fully out of circulation and are still attached to 
the vasculature, which is present both above and underneath the tumor-like structure.  
To more closely study the mechanism behind accumulation of liposomes in tumors we 
injected blue fluorescent dextran into the circulation of Tg(fli1:EGFP)y1 embryos with 
Melmet 5 or HEK293 tumor-like structures. Within the limited time frame that dextran stays 
restricted to the blood vessels (up to 30 mins 
29
) it did not passively leak into the tumor mass 
(Supplementary Figure 1). This suggests that liposome accumulation in the tumor-like 
structures outside the vasculature is not due to non-specific leakage out of the vasculature. 
To our knowledge we are the first to image the accumulation of NPs to human tumor-
like structures established in the ZF embryo model. No other animal model currently exists 
where NP circulation through tumor tissues can be monitored so easily over time. The 
accumulation of liposomes in the tumor masses was especially rapid and apparently 
selectively, in spite of the fact that our NPs did not contain molecules that could actively 
target the NPs to the tumor cells 
73
. After only 2-5 h high levels of PEG liposomes 
accumulated selectively in the tissue where the Melmet 5 or the HEK293 tumor-like 
structures resided. A plausible explanation for the leakage into both types of tumor-like 
structures is that the tumor cells secrete growth factors that affect the integrity of the 
vasculature locally. HEK293 cells express VEGF 
74, 75
, the most potent inducer of 
angiogenesis, and could be responsible for loosening the junctions between endothelial cells 
76
. 
Further, Melmet 5 cells activate in vitro HUVEC migration, tube formation and induce 
expression of pro-angiogenic growth factors 
77
. This leads us to speculate that a local 
activation of endothelial cells in the ZF embryo may lead to a destabilized vasculature. 
Whether this effect corresponds to the well-known phenomenon of enhanced permeability and 
retention (EPR) effect described for mammalian systems remains to be determined 
78
. The 
fact that we could not see leakage of dextran into tumor masses suggests that accumulation of 
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liposomes outside the vasculature is a regulated process rather than just passive NP leakage 
out of the blood vessels. Nevertheless, two different cell lines, one cancer (Melmet 5) and one 
tumorigenic cell line (HEK) were able to stimulate accumulation of NPs in the close vicinity 
of tumors. The patterns of NP-accumulation for the two types of tumor-like structures were 
slightly different, suggesting different mechanisms. Thus, the zebrafish embryo model can be 





Here we introduce the ZF embryo and optical tweezers as novel tools for testing novel 
NPs aimed for cancer therapy. We present a strategy that can be used to screen for novel anti-
cancer NPs in order to identify leading candidates for subsequent testing in more conventional 
animal models such as mouse. Undesirable anti-cancer NP properties such as uptake by 
macrophages and attachment to endothelia are easily and rapidly identified and characterized 
in ZF embryos. Conversely, the system also allows desirable properties to be monitored, such 
as NP accumulation in tumor tissues. This in vivo model opens the way for future systematic 
studies of NPs in dynamic models of human cancer. This will greatly facilitate the search for 
the most effective materials and surface properties to make NPs for tumor targeting purposes. 
In this study, we chose PEG as a model molecule to add stealth properties to NPs as it has 
been extensively studied and its effects are well known. In accordance with results in the 
literature, we found that PEG lowers NP uptake by macrophages and increases NP circulation 
times; moreover, the zebrafish embryo model is sensitive enough to discriminate between 
PEG-coated and ‘naked’ NPs. This opens up for testing of more experimental surface coating 
of NPs in order to identify novel promising candidates for cancer therapy.  
Additionally, we demonstrate desirable effects of PEG on NPs in vitro as macrophages 
do not adhere to PEG-coated NPs. Our optical tweezer experiments further provide detailed 
data regarding NP surface coating and how this affects interactions with macrophages and 
cancer cells. A stealth effect could further be observed in vivo as PEG coated NPs had longer 
circulation times and lower affinity for endothelium in ZF embryos. Finally, liposome NPs 
were shown to passively accumulate in vivo in tumor-like structures comprised of human 
cancer cells.  
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Figure legends 
Figure 1. ZF injections and establishment of human tumor-like structures. (A) 
Illustration of injection sites for human cancer cells and NPs. The red line illustrates the 
dissemination route for cancer cells via blood vessels to the most frequent site of 
extravasation (White Square) where tumor-like structures were established. The entire 
vasculature is visible as a result of circulating fluorescent nanoparticles. (B) The melanoma 
cell line Melmet 5 (red) had the capacity to establish multiple tumor-like structures in the tail. 
(C) A Melmet 5 tumor-like structure (red) in the tail showing its typical orientation relative to 
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the vasculature (green), in between blood vessels. (D) The vasculature (green) is pushed aside 
where the Melmet 5 cells are growing (arrow). (E) HEK293 cells established single tumor-
like structures in the tail. (F) A HEK293 tumor-like structure (red) and its orientation relative 
to the vasculature (green). These cells had the capacity to grow peripheral to the vasculature 
(arrow). (G) The HEK293 cells also pushed the vasculature aside (arrow) when located in 
between blood vessels (green). (H) Quantification of Melmet 5 tumor-like structure sizes in 
individual embryos over a period of 6 dpi (p<0.05). (I) Quantification of HEK293 tumor-like 
structure sizes in individual embryos over a period of 6 dpi (p>0.05). N = 6. Scale bars: 100 
µm (C, D, F, G). 
 
Figure 2. NoPEG PSNPs had short circulation times in zebrafish embryos. (A) NoPEG 
blue fluorescent 1000 nm PSNPs adhered to the endothelium (green) shortly after injection 
into Tg(fli1a:EGFP)
 y1
 embryos having green fluorescent vasculature. (B) 20 seconds post 
injection of fluorescent 200 nm NoPEG PSNPs (green) they were circulating (asterisk) but 
also adhered to the endothelium, as evident by intense green dots (red arrows). (C) 140 
seconds post injection low levels (compared to (B)) of NoPEG PSNPs (green) were in 
circulation (white asterisk). NoPEG PSNPs adhered to the DLAV (white arrow), caudal artery 
(yellow asterisk), caudal vein (red asterisk) and the small vessels in between them (red arrow). 
Very little adhesion was observed in the intersegmental vessels (yellow arrow). (D) 20 
minutes post injection NoPEG PSNPs (green) were completely cleared from the circulation. A 
speckled pattern appeared as a result of NoPEG PSNPs (green) adhering to endothelial cells. 
(E) Circulating NoPEG fluorescent liposomes (green) in a wild type embryo results in a 
complete representation of the vasculature. Low levels of liposomes were infrequently 
observed to adhere to the endothelium (white arrow). (F) 20 hours post injection into mpeg 
cherry embryos having red fluorescent macrophages; NoPEG liposomes (green) were all 
cleared from circulation and taken up by the red macrophages (yellow dots, arrows). All 
experiments N = 10, representative images are shown. Scale bars: 200 µm (A-C, E,F); 100 
µm (d). 
 
Figure 3. In vitro characterization of the PEGylation effect. (A) Transmission EM image 
of negatively stained 200 nm PEG liposomes (Table 1). (B) High levels of 200 nm NoPEG 
PSNPs (green) were taken up by RAW macrophages (Figure 3B-1). Conversely, the 200 nm 
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PEG PSNPs (green) were taken up in much lower levels (Figure 3B-2). (C) Flow cytometry 
analysis showed a 2-fold higher uptake by macrophages of NoPEG PSNPs (green) compared 
to PEG PSNPs (yellow). Control macrophages defining the baseline are shown in grey. (D) 
Green fluorescent NoPEG (Figure 3D-1) and PEG (Figure 3D-2) liposomes were taken up by 
RAW macrophages in roughly equal amounts after 10 minute of incubation. Scale bars: 1 µm 
(A); 50 µm (B, D). 
 
Figure 4. Quantification of the PEGylation effect using optical tweezers. (A) NoPEG 
1000 nm PSNPs adhered more frequently to RAW macrophages than NoPEG 500 nm PSNPs 
(p = <0.01). (B) A NoPEG 1000 nm PSNP stimulated a macrophage to engulf it within a 
minute after the first contact (left panel, arrow) while a PEG PSNP of the same size did not 
stimulate such a response (right panel, arrow). (C) The presence of PEG on the surface of 
PSNPs eliminated the size effect, as 1000 nm and 500 nm PEG PSNPs showed similar 
adhesion levels to RAW macrophages (p = >0.05). (D) Pre-incubation of PSNPs in serum did 
not affect binding profiles to RAW macrophages. PEG coating prevented binding, while 
serum incubation with NoPEG PSNPs did not result in increased binding, as compared to (A) 
(p = <0.01). (E) PEGylation of PSNPs inhibited adhesion of these beads to cancer cells. Pre-
incubation of PSNPs in serum did not interfere with the PEG-effect as all adhesion to Melmet 
5 was blocked. The presence of serum proteins lowered the binding of NoPEG PSNPs to 
Melmet 5 as PBS-incubated NoPEG PSNPs, lacking serum proteins, displayed higher level of 
adhesion. Scale bars: 10 µm (B). 
 
Figure 5. PEGylation prolonged NP circulation time in zebrafish embryos. (A) 200 nm 
PEG PSNP (green) in circulation of a wild-type embryo 20 seconds post injection (white 
asterisk). Adhesion of these NPs to the vasculature, evident as green intense spots, was only 
observed in the small vessels (red arrow) between the caudal artery (yellow asterisk) and 
caudal vein (red asterisk). (B) 140 seconds post injection into a wild type embryo relatively 
high level of green fluorescent PEG PSNPs (compared to (A)) were still in circulation (white 
asterisk). These NPs did not adhere to the DLAV (white arrow), nor to the caudal artery 
(yellow asterisk) nor caudal vein (red asterisk) and only visibly adhered to the small vessels 
between them (red arrow, green intense spots). (C) Maximum circulation time of PEG PSNPs 
(green) was 60 minutes. They were not associated with, or taken up by macrophages (red) in 
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the mpeg cherry embryo. (D) PEG liposomes (green) injected into an mpeg cherry zebrafish 
embryo with fluorescent macrophages (red) circulated 24 h post injection. Fractions of 
liposomes were taken up by macrophages (yellow, arrow) but the majority was still in 
circulation, as evident by making the vasculature visible. (E) 46 h post-injection a full 
representation of the vasculature of a wild type embryo was observed as a consequence of 
circulating liposomes (green). They were continuously but slowly taken up by macrophages 
(green dots, arrows). (F) By 70 h post injection all PEG liposomes was cleared from 
circulation of a wild type embryo as they were taken up by macrophages (green dots, arrows). 
Importantly, no adhesion of liposomes to the endothelium was observed. All experiments N = 
10, representative images are shown. Scale bars: 200 µm (A-F). 
 
Figure 6. Liposomes accumulated passively into human tumor-like structures. (A) 2 dpi 
Melmet 5 tumor-like structures (red) accumulated liposomes (green) after 2 h of circulation. 
(B) An image showing the tail of a wild type embryo. Liposomes (green) only accumulated at 
the site of the Melmet 5 tumor-like structures (red). (C) Tumor-like structures comprised of 
HEK293 cells (red) also had the capacity to accumulate liposomes (green). (D) A control 
embryo injected with liposomes (green), without cancer cells, show the distribution of 
liposomes after 5 h circulation. Minute levels of liposomes were taken up by macrophages 
(arrows) and were only visible with considerably higher exposure time than the images in (A-
C). (E) 3D view of a confocal stack of a 2 dpi Melmet 5 tumor-like structure (red) with 
accumulated liposomes (green) after 3 h of circulation. Liposomes seemed to associate tightly 
with the cancer cells, mostly at the periphery of the tumor-like structure. A sub-fraction of the 
liposomes were able to penetrate deeper into the tumor-like structure (arrow). (F) 3D view of 
a confocal stack of a 2 dpi HEK293 tumor-like structure (red) with accumulated liposomes 
(green) after 5 h of circulation. The liposomes had a loose association with the tumor-like 
structure as they concentrated in the area around the cancer cells, and did not interact with the 
cancer cells directly. Experiments shown in A-D, N = 8. Representative images are shown. 
Scale bars: 100 µm (A, C); 300 µm (B); 200 µm (D); 30 µm (E, F). 
 
Supplementary Figure 1. No leakage of dextran into tumor-like structures. (A) Confocal 
stack of a Melmet 5 tumor-like structure (red) surrounded by the vasculature (green) in which 
the dextran flows (blue). The dotted arrow indicates the direction of the blood flow. We could 
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not observe any leakage of 10 kDa dextran into the tumor-like structure. A blood vessel 
behind the tumor-like structure (arrow) is transporting dextran but it is not leaking out. (B) 
Confocal image of a HEK293 tumor-like structure (red, asterisk) located next to a blood 
vessel (green) transporting dextran (blue). The dotted arrow indicates the direction of the 
blood flow. No leakage of dextran into the tumor-like structure could be observed. N = 4. 
Scale bars: 30 µm.  
Supplementary video 1. 200 nm green fluorescent NoPEG PSNPs in zebrafish embryo circulation 20 seconds 
post injection. 
Supplementary video 2. 200 nm green fluorescent NoPEG PSNPs in zebrafish embryo circulation 140 seconds 
post injection 
Supplementary video 3. 1000 nm NoPEG PSNP adhering to a RAW macrophage in vitro. 
Supplementary video 4. 1000 nm PEG PSNP do not adhere to a RAW macrophage in vitro. 
Supplementary video 5. 200 nm green fluorescent PEG PSNPs in zebrafish circulation 20 seconds post 
injection 
Supplementary video 6. 200 nm green fluorescent PEG PSNPs in zebrafish circulation 140 seconds post 
injection 
Supplementary video 7. 200 nm green PEG liposomes in zebrafish embryo circulation 24 h post injection. 
Supplementary video 8. 200 nm PEG green liposomes in zebrafish embryo circulation 46 h post injection. 
Supplementary video 9. 200 nm PEG green liposomes taken up by macrophages 70 h post injection 
Supplementary video 10. 200 nm green PEG liposomes circulating in zebrafish embryo with red tumor-like 
structures. 
Supplementary video 11. 200 nm green liposomes accumulated in Melmet 5 tumor-like structure. Tumor-like 
structures are invisible but the embryo is the same as in Figure 6B where the tumor-like structures can be seen.  
Supplementary video 12. 3D view of a confocal stack (ImageJ) of a red Melmet 5 tumor-like structure with 
accumulated green liposomes. 
Supplementary video 13. 3D view of a confocal stack (ImageJ) of a red HEK293 tumor-like structure with 
accumulated green liposomes. 
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